tbuckley/cabot-search huggingface dataset:
Oncology provider perceptions of shared-decision making.
Authors: Nila Sathe, Cate Polacek, Sunnie Fenk, Wendy Rossi, Roni Christopher
Journal: Journal of Clinical Oncology (2019)

e23168 Background: Adoption of shared decision making (SDM), a key strategy for improving patients’ care experience, may be limited. We explored oncology professionals’ SDM perceptions to understand patient-provider decision-making communication. Methods: Semi-structured phone interviews or web-based surveys with purposively recruited participants from a range of perspectives to increase generalizability. Content analysis to identify overarching themes. Results: Respondents (n = 20) valued SDM but described challenges including: Evolving and variable communication needs. Evolving care trajectories constrain full SDM discussions. Differences in goals in curative or palliative situations dictate different approaches. Communication along care continuum. Providers noted that discussions of elements of care occur with multiple providers and staff, potentially in a piecemeal fashion. Communicating about costs. Costs vary considerably in terms of cost to the patient and to the system. Impact on care is more than a simple higher/lower dichotomy. Directing decisions vs. fostering discussion: Most respondents understood a “literature-based” SDM definition, but some conflated patient education and SDM. Some implied “nudging” patients toward choices vs. open discussion. Balancing clinical imperatives and patient preferences. Respondents noted balancing professional imperatives to share information with patient values. External influences on communication. Families were seen as a help and hindrance to SDM, particularly when care goals differ. Cultural meanings ascribed to cancer also vary. Decision making style. Participants suggested that patients approach decision making from overarching mindsets regarding engagement (e.g., prioritizing provider input). Conclusions: Respondents valued communication and SDM but described challenges in exigencies of care delivery, provider attitudes, and patient influences. Respondents’ discussion of challenges suggests that exploiting communication opportunities across the care trajectory and deliberate consideration of patients’ preferences for decision-making conversations could help to inform/prime communication and potentially improve SDM processes.
Altered expression of CSF3R splice variants impacts signal response and is associated with SRSF2 mutations
Authors: Amanda Lance, Lawrence J. Druhan, C. Greer Vestal, Nury M. Steuerwald, Alicia Hamilton, Mathew Smith, Andrea Price, Elise Tjaden, Andee N. Fox, Belinda R. Avalos
Journal: Leukemia (2019)
Hair loss and lymphadenopathy
Authors: Sheng Li, Liming Wu
Journal: BMJ (2019)

A 19 year old man presented with a two month history of lumps behind the ears and in the groin, and scalp hair loss. He had felt generally unwell during the past month. Physical examination revealed painless generalised lymphadenopathy in the postauricular (fig 1), posterior cervical, and inguinal regions. He had patchy, non-cicatricial (non-scarring) alopecia with a moth eaten appearance (5 mm diameter patches) all over the scalp (fig 1). Fungal microscopy was negative. Dermoscopy revealed yellow …
Surgery of Genito-Urinary Organs.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts
Authors: Paula F. Orlandi, Jing Huang, Masafumi Fukagawa, Wendy Hoy, Vivekanand Jha, Kook-Hwan Oh, Laura Sola, Paul Cockwell, Adeera Levin, Harold I. Feldman, Wendy E. Hoy, Zaimin Wang, Jianzhen Zhang, Helen G. Healy, Paul Cockwell, Anthony Fenton, Paula F. Orlandi, Lisa Nessel, Alan Go, Lawrence Appel, Harold I. Feldman, Kook-Hwan Oh, Curie Ahn, Dong Wan Chae, Seung Hyeok Han, Adeera Levin, Ognjenka Djurdjev, Mila Tang, Laura Sola, Pablo G. Rios, Liliana Gadola, Masafumi Fukagawa, Takayuki Hamano, Naohiko Fujii, Takahiro Imaizumi, Vivekanand Jha, Ashok Kumar Yadav, Vivek Kumar
Journal: Kidney International (2019)
Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis.
Authors: Mark A. Eckardt, Danielle S. Graham, Arun S. Singh, Bartosz Chmielowski, Noah Federman, Anusha Kalbasi, Nicholas M. Bernthal, Susan V. Bukata, Francis J. Hornicek, Jane Yanagawa, Benjamin D. Levine, Kambiz Motamedi, Leanne L. Seeger, Jeffrey J. Eckardt, Frederick R. Eilber, Sarah M. Dry, Scott D. Nelson, Frederick C. Eilber
Journal: Journal of Clinical Oncology (2019)

11020 Background: With more than 80 different histologic subtypes, sarcomas are a unique pathologic challenge. As therapeutic decisions have become histology-specific, obtaining an accurate pathologic diagnosis is critical in guiding treatment decisions. The aim of this study is to determine the discordance between the diagnosis rendered by an external non-specialized pathologist and pathologic re-review by a specialized sarcoma pathologist at a high-volume sarcoma center. Methods: Patients who presented at the UCLA Multidisciplinary Sarcoma Conference (MSC) in 2017 that had a pathologic diagnosis from an outside facility were included in this study. All specimens underwent pathologic re-review at UCLA by an experienced sarcoma pathologist. The pathology was classified as concordant (identical diagnoses), minor discordance (difference with minor impact on prognosis/therapy) and major discordance (difference with significant impact on prognosis/therapy). Results: 1350 patients were presented at the UCLA MSC in 2017. Of the 635 new patients, 196 presented with an outside pathologic diagnosis and underwent pathologic re-review at UCLA. 44% (n = 87) were concordant, 22% (n = 43) had minor discordance, and 34% (n = 66) had major discordance. Major discordance included substantial discrepancies in histologic subtype (n = 24, 36%), benign/malignant mismatch (n = 23, 35%), diagnostic from non-diagnostic (n = 12, 18%) and major grading discrepancy (n = 7, 11%). Major discordance was most often seen in biopsies [needle (n = 27, 32%), incisional (n = 30, 44%)] as compared to resection (n = 9, 21%). Conclusions: 56% of external non-specialized sarcoma pathologic diagnoses were discordant from specialized sarcoma pathologist review, 34% of which were major discordances. Pathologic re-review of a presumed sarcoma by a specialized sarcoma pathologist is critical for both patient care and investigational studies. [Table: see text]
Modeling ASXL1 Mutation Revealed Myelodysplasia Caused By Derepression of p16Ink4a through Aberrant PRC1-Mediated Histone Modification
Authors: Masahiro Uni, Yosuke Masamoto, Tomohiko Sato, Shunya Arai, Eiji Hara, Mineo Kurokawa
Journal: Blood (2017)
Implementation of Supervised Exercise Therapy for Patients With Symptomatic Peripheral Artery Disease: A Science Advisory From the American Heart Association
Authors: Diane Treat-Jacobson, Mary M. McDermott, Joshua A. Beckman, Marsha A. Burt, Mark A. Creager, Jonathan K. Ehrman, Andrew W. Gardner, Ryan J. Mays, Judith G. Regensteiner, Dereck L. Salisbury, Erica N. Schorr, M. Eileen Walsh
Journal: Circulation (2019)

Patients with lower-extremity peripheral artery disease (PAD) have greater functional impairment, faster functional decline, increased rates of mobility loss, and poorer quality of life than people without PAD. Supervised exercise therapy (SET) improves walking ability, overall functional status, and health-related quality of life in patients with symptomatic PAD. In 2017, the Centers for Medicare & Medicaid Services released a National Coverage Determination (CAG-00449N) for SET programs for patients with symptomatic PAD. This advisory provides a practical guide for delivering SET programs to patients with PAD according to Centers for Medicare & Medicaid Services criteria. It summarizes the Centers for Medicare & Medicaid Services process and requirements for referral and coverage of SET and provides guidance on how to implement SET for patients with PAD, including the SET protocol, options for outcome measurement, and transition to home-based exercise. This advisory is based on the guidelines established by the Centers for Medicare & Medicaid Services for Medicare beneficiaries in the United States and is intended to assist clinicians and administrators who are implementing SET programs for patients with PAD.
Ideal Total Joint Arthroplasty Antibiotic Prophylaxis Unknown—Reply
Authors: Westyn Branch-Elliman, William O’Brien, Kalpana Gupta
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials
Authors: D. R. Spigel, C. Shah, P. Lorigan, R. McNally, M. Renschler, J. Oliver
Journal: Journal of Clinical Oncology (2009)

e19019 Background: Amrubicin (AMR) is a third-generation synthetic anthracycline and a potent topoisomerase II inhibitor approved in Japan for the treatment of lung cancer. In Japanese pre and postmarking studies, AMR treatment was not associated with cardiotoxicity. The purpose of this analysis was to determine if AMR treatment of Western patients (pts) is associated with anthracycline-induced cardiomyopathy. Methods: To evaluate risk of cardiomyopathy, LVEF was measured by echocardiogram or by multiple gated acquisition (MUGA) scan and pooled from pts enrolled in 2 trials of IV AMR, 40 mg/m 2 /day x 3 days q 21 days for second-line treatment of sensitive or refractory SCLC. Pts with measurable disease, ECOG PS 0–2, LVEF ≥50%, and prior platinum-based treatment were assessed at baseline (BL), cycles 3, 6, then every 2 cycles, and end of treatment. Pts were to be assessed by the same method (ECHO or MUGA) throughout the study. Pts with a persistent ≥20% decrease in LVEF during treatment were to be removed from the study. Results: 112 patients were treated (sensitive n=43, median 6 cycles; refractory, n=69, median 5 cycles) and had at least 1 LVEF assessment. Median age was 63 years and median BL LVEF was 60%. Changes in LVEF from baseline were minimal ( Table ) and similar across cumulative dosing groups including 15 pts who received a cumulative dose of &gt;1,000 mg/m 2 AMR. Two refractory pts (1.8%) experienced drops in LVEF &gt;20%. One had BL LVEF of 85%, then 60% at cycle 3, and 70% subsequently with ongoing therapy. The second, with a history of cardiomegaly, had LVEF of 55% at BL, cycle 3, and 5 by ECHO, and 29% at the time of progression after cycle 9 (cumulative AMR dose 840 mg/m 2 ) by MUGA. The patient died due to progressive disease with no evidence of CHF. Conclusions: In this pooled analysis of SCLC pts, LVEF remained stable even in pts with cumulative AMR dosing &gt;1,000 mg/m 2 . AMR for second-line treatment of SCLC does not appear to cause anthracycline-related cardiomyopathy. [Table: see text] [Table: see text]
Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.
Authors: Susana Benlloch, Miquel Taron, Maria Luisa Botero, Jordi Bertran-Alamillo, Clara Mayo, Ana Gimenez Capitan, Itziar de Aguirre, Cristina Queralt, Jose Luis Ramirez, Rafael Rosell, Barbara Klughammer, Mariette Schlegel, David Chen, Walter Bordogna, Ju Ruey-Jiuan Lee, Barbara Kovach, Patrick O'Donnell, Lin Wu, H. Jeffrey Lawrence
Journal: Journal of Clinical Oncology (2012)

10596 Background: Anti-EGFR inhibitors are superior to chemotherapy in first-line therapy of advanced EGFR-mutant NSCLC. The EURTAC trial was a randomized Phase III trial of erlotinib vs. chemotherapy in patients with EGFR-mutant NSCLC. Interim results showed significant improvement in progression-free survival (R. Rosell, ASCO 2011). An accurate rapid in vitro diagnostic for EGFR mutations is needed to select patients for this therapy. Methods: Prospective EGFR mutation testing for the trial was performed on laser-capture microdissected tumor cells using a combination of 3 lab-developed tests (LDTs), including a Length Analysis of Fluorescently-labeled PCR (Genescan) method for exon 19 deletions, a Taqman-based PCR assay for exon 21 mutation with laser-capture macrodissected tumor cells, and secondary Sanger sequencing. A subset of samples from the trial was retrospectively tested with an AS-PCR assay (cobas EGFR mutation test) which detects L858R and &gt; 29 exon 19 deletions. The test provides automated results within 8 h; the DNA required can be isolated from one 5-micron tissue section. Four methods were compared: AS-PCR assay, LDT, direct Sanger sequencing and massively parallel sequencing (MPS; 454, Branford, CT). Results: LDT results were obtained for 1044 screened patients. Residual tumor blocks were available for 487 patients (47%), including 303 wild-type, 172 mutant (135 enrolled on the trial) and 12 inconclusive cases by the LDT. Comparison of AS-PCR and LDT results showed a positive percent agreement (PPA) – 93.7% (CI 88.8%, 96.5%), and negative percent agreement (NPA) – 97.5% (94.9%, 98.8%). Comparison of AS-PCR and Sanger results showed a PPA of 96.6% (91.7%, 98.7%) but an NPA of 88.3% (84.1%, 91.5%). Among 34 AS-PCR + /Sanger - case, MPS confirmed the presence of exon 19 deletions in 25 cases and L858R mutations in 7. Direct comparison of AS-PCR and MPS results showed a PPA of 93.1% (88.1%, 96.1%) and NPA of 97.7% (95.0%, 98.9%). Clinical outcomes for cases with mutations detected by the AS-PCR test will be presented. Conclusions: The AS-PCR assay was highly concordant with the LDT and MPS, and more sensitive than Sanger sequencing.
Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?
Authors: Nisha Unni, Carlos L. Arteaga
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Miro2 Regulates Inter-Mitochondrial Communication in the Heart and Protects Against TAC-Induced Cardiac Dysfunction
Authors: Yangpo Cao, Chunling Xu, Jingjing Ye, Qihua He, Xingzhong Zhang, Shi Jia, Xue Qiao, Chenglin Zhang, Ruxia Liu, Lin Weng, Yingying Liu, Limei Liu, Ming Zheng
Journal: Circulation Research (2019)

Rationale: The constrained mitochondria in cardiomyocytes communicate with each other, through mitochondrial kissing or nanotunneling, forming a dynamically continuous network to share content and transfer signals. However, the molecular mechanism of cardiac inter-mitochondrial communication is unclear. Objective: To determine the molecular mechanism underlying the robust inter-mitochondrial communication and its pathophysiological relevance in the heart. Methods and Results: By mitochondria-targeted expressing the photoactivatable green fluorescent protein, we revealed that most mitochondrial nanotubes bridge communicating mitochondrial pairs were associated with microtubules. Miro2 (mitochondrial Rho GTPase), the outer mitochondrial membrane protein which usually mediates mitochondrial transport within cells, accompanied with mitochondrial nanotubes along microtubules in adult cardiomyocytes. Adenovirus mediated expression of Miro2 in cardiomyocytes accelerated inter-mitochondrial communication through increasing mitochondrial nanotunneling and mitochondrial kissing between adjacent mitochondrial pairs. In transverse aortic constriction-induced hypertrophic mouse hearts Miro2 protein was declined, accompanied with decreased inter-mitochondrial communication. Miro2 transgenic mice showed ameliorated cardiac function, increased mitochondrial nanotube formation and inter-mitochondrial communication, and improved mitochondrial function after transverse aortic constriction. E3 ubiquitin ligase Parkin was increased in transverse aortic constriction mouse hearts and phenylephrine stimulation-induced hypertrophic cardiomyocytes. Inhibition of proteasome blocked phenylephrine-induced decrease of Miro2, and Parkin overexpression led to the decrease of Miro2. Conclusions: Mitochondrial Miro2 expression levels regulate inter-mitochondrial communication along microtubules in adult cardiomyocytes, and degradation of Miro2 through Parkin-mediated ubiquitination contributes to impaired inter-mitochondrial communication and cardiac dysfunction during hypertrophic heart diseases.Visual Overview: An online visual overview is available for this article.
TGFBR1 SNP’s are a genetic marker potentially useful for colorectal cancer screening.
Authors: Marc Pauly, Garry Mahon, Brigitte Metzger, Alain Menzel, Ben Weber, Mario-A Dicato
Journal: Journal of Clinical Oncology (2013)

e14591 Background: Colonoscopy (CS) used for colorectal cancer (CRC) screening is relatively expensive and intrusive. We have shown that CRC in Caucasian patients have a high frequency of certain TGFBR1 SNP’s relative to normal controls. Here we extend the results to these SNP frequencies in normal tissue of the patients and the concordance of three different SNP’s in the TGFBR1 gene across patients and subjects. Methods: Tumor samples were obtained from 188 CRC patients and from 98 healthy control. After gDNA extraction, selected amplicons were amplified by PCR, followed by melting curve analysis. The statistical evaluation of the genotype frequency for the different SNPs comparing CRC patients with controls was carried out using logistic regression. Results: Results previously reported were confirmed:- a highly significant association between TGFBR1 SNP genotype and colorectal cancer (P&lt;0.000001). For example, with the TGFBR1 SNP rs334348, the frequency of the GG genotype was 43% for patients but 11% for controls, while the AA frequency was only 18% for patients and 43% for controls. All CRC patients and controls were typed for three SNP's in the TGFBR1 gene and the concordance was found to be perfect. That is, only 3 of the 27 possible genotypes were observed:- (i) rs334348, AA; rs334349, AA; rs1591, CC; (ii) rs334348, AG; rs334349, AC; rs1591, CT; and (iii) rs334348, GG; rs334349, CC; rs1591, TT. Blood and tumor samples from patients had the same identical SNP pattern. Conclusions: The perfect concordance of the three SNP types in tumors and leukocytes shows that it reflects the underlying genotype of the patient rather than a somatic mutation in the tumour. Thus SNP type is a characteristic of subjects and a potential genetic marker for CRC susceptibility. We suggest that subjects aged 50 years or older be offered a test for a TGFBR1 variant. In case of a positive result, subjects should be informed that they are at risk of CRC, and strongly encouraged to have a colonoscopy. For this suggestion to become a definitive recommendation a cost-effectiveness analysis of the use of TGFBR1 SNP typing would be useful ( although such typing is inexpensive) and a prospective study of colonoscopy with TGFBR1 typing is mandatory.
CD300f is a potential therapeutic target for the treatment of food allergy
Authors: Shino Uchida, Kumi Izawa, Tomoaki Ando, Hiromichi Yamada, Koichiro Uchida, Naoko Negishi, Ayako Kaitani, Akie Maehara, Masakazu Nagamine, Anna Kamei, Ayako Takamori, Keiko Maeda, Nobuhiro Nakano, Toshiaki Shimizu, Hideoki Ogawa, Ko Okumura, Akihito Nagahara, Sumio Watanabe, Jiro Kitaura
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.